Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 197

When directors sell, should you sell too?

When directors buy or sell shares in their company, most people believe they are sending a strong signal to the market about the firm’s prospects. But how strong is the correlation between director trades and share price movements? And should you buy or sell because a director has too? We did some research to get closer to the truth.

It seems reasonable to think that company directors have better insight than the rest of us into the performance and prospects of a business, and that they may be more willing to buy when they see a rosy outlook, and sell when the outlook is dim.

Of course, regulation and governance should greatly limit the extent to which company insiders take advantage of their privileged position, but one suspects that these constraints may mitigate against the application of insider insight, rather than completely eliminate it.

This discussion has become more topical recently, with some high-profile examples of director selling that now look to be fairly prescient. These include cases like Aconex, Sirtex, Bellamys, Vocus, Brambles and Healthscope, where directors managed to sell shares ahead of falling prices.

Don’t make too much of recent experience

There’s no doubt that director sales have been telling in these recent examples, but there is a strong tendency for investors to extrapolate from limited recent experience, and it’s always good to be a little wary of this. A better approach is to look at what the data says over a reasonable time period to try to gauge objectively how much comfort we can draw from insider purchases, and how much concern we should feel when they sell.

The academic research evidence has been a bit mixed. Some studies have shown that trades by company insiders contain information, but others find little effect, and good research evidence for the Australian market is lacking.

We did some research on ASX director trades. Our work is not of the quality that you might expect from published academic research, but it offers deeper insight than anecdotes.

Our analytical process

  • We downloaded the pdfs of ASX300 company announcements made over the past eight years where the title of the announcement indicated a “change in director’s interest” or “Appendix 3Y” (but excluded initial and final director’s interest notices).
  • We scanned the text of these announcements and used some rules to identify cases where the ‘Nature of change’ section indicated an on-market trade, and excluded cases where the change appeared to result from an issue of shares under company incentive plans and the like.
  • We used some further rules to extract numbers from the ‘Interest Acquired’, ‘Interest Disposed’ and ‘Value/Consideration’ sections of the announcements. We will have missed some trades for various reasons but we had a good representative sample of either years of data.
  • We then looked back six months (ie. considered director trades made in the six months prior to our observation date) and examined risk adjusted returns over the subsequent three months.

Our research findings

  • Director selling appears to contain more information than director buying. This is consistent with some academic research which indicates selling is a more powerful signal than buying.
  • On average, we found that around 20% of companies had one or more director share sales occurring in any given six month look-back period. Interestingly, the most recent data shows a relatively high proportion of director selling, which could indicate a general perception by directors that prices currently are at elevated levels.

  • Seasonality to director selling is apparent, with the peaks in January indicating that the second half of the calendar year – and the final quarter in particular – is the most popular time to sell.
  • Because the director sales occur in a relatively small proportion of our universe (about 20%), we need to keep the returns analysis simple. We divide our companies into two groups: those where no director sales have been identified in the past six months, and those where at least one director sale has been found. We form equal-weighted portfolios from these two groups and rebalance every three months.
  • As a general rule, the companies where directors had sold shares tended to perform worse than companies where no director sales had occurred. On average the difference between the two groups seems to run to a couple of percentage points per year, but the pattern is far from consistent. Most of the performance differential occurred between mid-2009 and late-2012. In recent years, we have seen only a small differential (although the final quarter of 2016 was a good time to avoid companies with director sales).

It’s worth watching director sales

We conclude that when company directors sell shares, it is not necessarily an overwhelming signal that others should follow suit. However, it clearly should be considered as part of the analysis. As is often the case, common sense should prevail, as a sale should prompt you to:

  • Consider the specific circumstances and whether it may be motivated by a negative view on firm prospects or something more benign.
  • Think about whether the relevant director has a large information advantage and is much better placed than you to gauge long term value.
  • Reflect on your valuation assumptions and importantly, your level of conviction in them.

 

Tim Kelley is Head of Research and Portfolio Manager of The Montgomery Fund. This article is general information that does not consider the circumstances of any individual.

 

6 Comments
SMSF Trustee
April 19, 2017

As I said in a comment on a similar article recently, if there is any share price performance information in watching director sales then we need to lobby the regulator to force companies to change the way they open windows for insiders to transact. It should be illegal for anyone to be able to profit from knowing things that the market as a whole does not know. If I happened to know something and acted on it, I'd be liable to an insider trading charge. So should directors and employees. It's unfair to the rest of us if they can sell before we know what they do.

Peter
April 12, 2017

Risk adjusted returns over the subsequent THREE MONTHS??
You do mean subsequent 3 years right?
The first is noise, the second is possibly a signal.

Tim
April 19, 2017

Hi Peter. Keep in mind that the "sell" portfolio will include all companies where a director sale occurred in the 6 months prior to portfolio formation, so we are effectively testing whether director selling is based on information that reveals itself within the subsequent 1 or 2 half-year reporting periods. In some cases I expect any "inside" information will be longer-dated than this but in many cases it won't.

Peter
April 19, 2017

Thanks Tim. I was looking at the perspective of the "buy" side. It might be interesting if we take company performance over the subsequent 3-5 years period after the relevant transaction, whether it is buy or sell.

Ashley
April 05, 2017

An ASX report a few years ago said that something like 25% of all director trades were not disclosed as required by law. They seemed not too concerned with that. I also recall US research that found that director purchases are more informative than director sales – the opposite of their findings here. Directors sell for a whole variety of reasons unrelated to the company (to pay tax, to pay ex-wives, to exercise options, to bail themselves out of jail, etc). But director buying often sends big signals about how they view the company’s prospects.

Bert
April 06, 2017

Or want the companies prospects to be seen possibly? I see this also fitting with a director talking up the future prospects of their company and how they wish their buying to be interpreted.

 

Leave a Comment:

RELATED ARTICLES

Insider sales can be a powerful warning

banner

Most viewed in recent weeks

Vale Graham Hand

It’s with heavy hearts that we announce Firstlinks’ co-founder and former Managing Editor, Graham Hand, has died aged 66. Graham was a legendary figure in the finance industry and here are three tributes to him.

Australian stocks will crush housing over the next decade, one year on

Last year, I wrote an article suggesting returns from ASX stocks would trample those from housing over the next decade. One year later, this is an update on how that forecast is going and what's changed since.

Avoiding wealth transfer pitfalls

Australia is in the early throes of an intergenerational wealth transfer worth an estimated $3.5 trillion. Here's a case study highlighting some of the challenges with transferring wealth between generations.

Taxpayers betrayed by Future Fund debacle

The Future Fund's original purpose was to meet the unfunded liabilities of Commonwealth defined benefit schemes. These liabilities have ballooned to an estimated $290 billion and taxpayers continue to be treated like fools.

Australia’s shameful super gap

ASFA provides a key guide for how much you will need to live on in retirement. Unfortunately it has many deficiencies, and the averages don't tell the full story of the growing gender superannuation gap.

Looking beyond banks for dividend income

The Big Four banks have had an extraordinary run and it’s left income investors with a conundrum: to stick with them even though they now offer relatively low dividend yields and limited growth prospects or to look elsewhere.

Latest Updates

Investment strategies

9 lessons from 2024

Key lessons include expensive stocks can always get more expensive, Bitcoin is our tulip mania, follow the smart money, the young are coming with pitchforks on housing, and the importance of staying invested.

Investment strategies

Time to announce the X-factor for 2024

What is the X-factor - the largely unexpected influence that wasn’t thought about when the year began but came from left field to have powerful effects on investment returns - for 2024? It's time to select the winner.

Shares

Australian shares struggle as 2020s reach halfway point

It’s halfway through the 2020s decade and time to get a scorecheck on the Australian stock market. The picture isn't pretty as Aussie shares are having a below-average decade so far, though history shows that all is not lost.

Shares

Is FOMO overruling investment basics?

Four years ago, we introduced our 'bubbles' chart to show how the market had become concentrated in one type of stock and one view of the future. This looks at what, if anything, has changed, and what it means for investors.

Shares

Is Medibank Private a bargain?

Regulatory tensions have weighed on Medibank's share price though it's unlikely that the government will step in and prop up private hospitals. This creates an opportunity to invest in Australia’s largest health insurer.

Shares

Negative correlations, positive allocations

A nascent theme today is that the inverse correlation between bonds and stocks has returned as inflation and economic growth moderate. This broadens the potential for risk-adjusted returns in multi-asset portfolios.

Retirement

The secret to a good retirement

An Australian anthropologist studying Japanese seniors has come to a counter-intuitive conclusion to what makes for a great retirement: she suggests the seeds may be found in how we approach our working years.

Sponsors

Alliances

© 2024 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.